Detalhe da pesquisa
1.
Human Herpesvirus-6 Reactivation and Disease Are Infrequent in Chimeric Antigen Receptor T-cell Therapy Recipients.
Blood
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635788
2.
Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Blood
; 143(16): 1656-1669, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38295333
3.
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Clin Infect Dis
; 78(4): 1022-1032, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37975819
4.
Unveiling the link between genetic alterations in gamma secretase and BCMA surface density in multiple myeloma.
Br J Haematol
; 204(2): 391-392, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38014717
5.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol
; 24(7): 811-822, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414012
6.
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.
Am J Transplant
; 23(3): 416-422, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748802
7.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood
; 137(3): 323-335, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967009
8.
Diagnosis and Management of Multiple Myeloma: A Review.
JAMA
; 327(5): 464-477, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35103762
9.
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Blood
; 134(19): 1585-1597, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558469
10.
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
Blood
; 134(15): 1247-1256, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31395601
11.
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 26(10): e247-e255, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589921
12.
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Blood
; 131(6): 611-620, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158362
13.
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.
Haematologica
; 105(6): 1731-1737, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582553
14.
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Am J Hematol
; 95(7): 775-783, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32243637
15.
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Haematologica
; 104(2): 380-391, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262560
16.
Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.
Biol Blood Marrow Transplant
; 24(11): 2211-2215, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30454872
17.
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Biol Blood Marrow Transplant
; 24(7): 1386-1391, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481870
18.
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.
Blood
; 127(3): 352-9, 2016 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26576864
19.
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.
Br J Haematol
; 176(4): 583-590, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28055107
20.
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Blood
; 125(13): 2111-9, 2015 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25628467